{"id":29,"date":"2026-07-14T18:10:15","date_gmt":"2026-07-14T18:10:15","guid":{"rendered":"https:\/\/blitzlab.eu\/blog-pt-141-kaufen\/"},"modified":"2026-10-23T23:36:58","modified_gmt":"2026-10-23T21:36:58","slug":"buy-pt-141","status":"publish","type":"page","link":"https:\/\/blitzlab.eu\/en\/blog-pt-141-kaufen\/","title":{"rendered":"PT-141 kaufen \u2013 Forschungsleitfaden"},"content":{"rendered":"
\n
Home<\/a>\u203a<\/span>Blog<\/a>\u203a<\/span>Buy PT-141 2026<\/span><\/div>\n\n

Buy PT-141 2026 \u2014 Bremelanotide for melanocortin receptor (MC3R\/MC4R) research (EU)<\/h1>\n

Peptide Research \u00b7 28 June 2026 \u00b7 12 min read \u00b7 Research Use Only<\/p>\n\n

\n In short:<\/strong> PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide, structurally derived from the sequence of the melanocortin peptide \u03b1-MSH. This research guide summarises, the published in-vitro and animal model literature<\/strong> zu PT-141 documented \u2013 from melanocortin receptor binding to CNS models. At BlitzLab as 10mg vial<\/strong> with batch-related Certificate of Analysis (COA)<\/a>, HPLC \u2265 99 %, EU delivery. Price: <\/strong>. For research use only (RUO).\n <\/div>\n
<\/svg> Scientific-factual research guide. Summarises published study observations. No health, dosage or application advice, no statement about suitability in humans. Research Use Only.<\/div>\n\n

PT-141 at a glance<\/h2>\n \n
Designation<\/th>PT-141 (Bremelanotide)<\/td><\/tr>\n
Identity<\/th>Synthetic cyclic heptapeptide, structurally derived from \u03b1-MSH<\/td><\/tr>\n
Synonyms<\/th>Bremelanotide, PT141<\/td><\/tr>\n
Research context<\/th>Melanocortin receptor binding models (MC1R\/MC3R\/MC4R), CNS models (in-vitro\/animal model)<\/td><\/tr>\n
CAS number<\/th>189691-06-3 (the batch-specific COA is authoritative)<\/span><\/td><\/tr>\n
Molecular formula<\/th>C50<\/sub>H68<\/sub>N14<\/sub>O10<\/sub><\/td><\/tr>\n
Form<\/th>Lyophilised powder (freeze-dried), sealed vial<\/td><\/tr>\n
Amount<\/th>10 mg per vial<\/td><\/tr>\n
Purity<\/th>\u226599% (HPLC), identity confirmed by LC-MS<\/td><\/tr>\n
Analysis<\/th>External third-party laboratory, batch-specific COA<\/td><\/tr>\n
Intended use<\/th>For Research Use Only (RUO)<\/td><\/tr>\n
Price<\/th> \u00b7 Shipping from Germany<\/td><\/tr>\n <\/table>\n\n

What is PT-141?<\/h2>\n

PT-141, with the international non-proprietary name Bremelanotide<\/strong>, is a synthetic Cyclic heptapeptide<\/strong> \u2013 a ring-closed peptide composed of seven amino acids. It is structurally derived from the sequence of the melanocortin peptide Alpha-MSH<\/strong> (alpha-melanocyte-stimulating hormone). Due to its cyclic architecture, PT-141 differs from linear peptides and is considered a well-characterised, defined reference substance from the melanocortin family in laboratory research. It is supplied as a stable lyophilised powder in a sealed vial (10 mg). CAS number (189691-06-3) and molecular formula (C50<\/sub>H68<\/sub>N14<\/sub>O10<\/sub>) are documented in the batch-related certificate of analysis.<\/p>\n\n

Molecular profile & target structure<\/h2>\n

As a heptapeptide, PT-141 consists of seven amino acid building blocks, which are closed into a ring; the molecular formula C50<\/sub>H68<\/sub>N14<\/sub>O10<\/sub> reflects this compact, nitrogen-rich structure. The structural similarity to Alpha-MSH<\/strong> places the substance into the context of the melanocortin system: In the literature, PT-141 is investigated as a ligand that binds to members of the Melanocortin receptor family<\/strong> binds \u2013 including MC1R, MC3R and MC4R. These receptors belong to the G-protein-coupled receptors. The combination of a defined, cyclic sequence and its relationship to a natural melanocortin peptide makes PT-141 a frequently used reference in receptor and neurobiological study models.<\/p>\n\n

What in-vitro and animal model studies document<\/h2>\n

The following summary reflects only what is described in the publicly accessible preclinical literature<\/strong> \u2013 it is not a statement about an effect or suitability in humans.<\/p>\n